Puget Sound Blood Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seattle WA United States (1944)

Organization Overview

First Clinical Trial
2006
NCT00810810
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

irradiated donor lymphocyte (1 trial)

leukoreduced blood components (1 trial)

Drugs in Phase 3 Trials (3)

granulocytes (1 trial)

sargramostim (leukine) (1 trial)

urea (1 trial)

Drugs in Phase 2 Trials (1)

acetylcysteine (mucomyst) (2 trials)

Drugs in Phase 1 Trials (1)

platelets (2 trials)

Drugs in Other Trials (1)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Neutropenia (Phase 3)

Purpura (Phase 1)

Purpura, Thrombocytopenic (Phase 1)

Purpura, Thrombotic Thrombocytopenic (Phase 1)

Thrombocytopenia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 8